Two cases of statin-induced rhabdomyolysis associated with mononeuropathy.

HMG-CoA reductase inhibitors (statins) are highly effective drugs for prevention of cardiovascular events in high-risk patients. Due to the widespread prescription of these agents, special attention should be given to their rare adverse effects when these may have severe outcomes. Here, we report two cases of localized rhabdomyolysis associated with mononeuropathy in patients taking statins and suggest possible explanations for this uncommon association. Close monitoring for myopathic/neuropathic events is warranted in high-risk patients with pre-existing neuropathies who are taking statins.